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Introduction
In 2005, the World Health Organization (WHO) recognized Chagas disease (CD; Trypano-
soma cruzi infection) as a neglected tropical disease (NTD) [1] and included it into the global
plan to combat NTDs [2]. The Target 3.3 of the United Nations Sustainable Development
Goals (UN/SDG) aims at ending the epidemics of NTDs by 2030 [3]. Mother-to-child (con-
genital/connatal) transmission is currently the main mode of transmission of T. cruzi over
blood transfusions and organ transplantations in vector-free areas within and outside Latin
America (LA). Based on recent demonstrations that congenital transmission can be prevented
[4–7], WHO has shifted its objective, in 2018, from control to elimination of congenital CD
(cCD) (road map reference documents in preparation).
This article summarizes the recommendations of the WHO Technical Group on “Preven-
tion and Control of Congenital Transmission and Case Management of Congenital Infections
with Trypanosoma cruzi” (WHO, Department of Control of Neglected Tropical Diseases). It
updates and completes the recommendations previously published in 2011 by the Technical
Group [8]. These consensual recommendations derive from discussions at technical meetings
convened by WHO in Murcia (Spain) on 9–10 October 2018 (II WHO Technical Consultation
on Control of Congenital Chagas disease in nonendemic countries, and specific meetings of
the Technical Group).
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Preliminary considerations on congenital transmission of T. cruzi
infection
Congenital transmission of T. cruzi infection is considered as such when (i) a neonate is born
to an infected mother (i.e., with positive serology and/or T. cruzi parasites circulating in the
blood) and (ii) T. cruzi parasites are identified in neonate blood at or after birth or (iii) specific
antibodies not of maternal origin are detected after birth and (iv) previous transmission to
infant by vectors and/or blood transfusion has been ruled out [8].
Mother-to-child transmission of CD can occur in infected women living in LA or outside
of LA if they have previously lived in LA endemic area and/or were born in LA or whose moth-
ers were born in LA. It can be recurrent at each pregnancy and from one generation to
another, leading to family clustering of congenital transmission cases [9]. This pattern of trans-
mission facilitates uncontrolled spread of CD over time, especially in urban areas in both
endemic and not endemic countries.
cCD remains an important global and neglected public health problem. Information on
prevalence in pregnant women and incidence of congenital cases is frequently lacking, and
epidemiological data mainly derive from estimations. WHO estimates that 1,125,000 women
in fertile age are infected with T. cruzi in LA, with an incidence of congenital infection of 8,668
cases/year [10]. The mean maternal–fetal transmission rate in chronic CD (the most frequent
phase of infection) in LA is estimated to 4.7% [11]. The number of babies that would need to
be tested per year has been estimated from 158,000 to 214,000 (mostly in Argentina, Brazil,
Bolivia, and Mexico) [12].
Through migrations from LA, an estimated 40,000 infected women of childbearing age
reside in the United States, where 60 to 315 congenital infections are expected to occur annu-
ally [13]. In Europe, the annual number of infected pregnant women has been estimated
between 1,347 and 2,521, with 20 to 184 cases of congenital transmission [14]. Cases of cCD
have been reported mainly in Spain (approximately 90%) but also in Sweden, Switzerland, and
more recently in Italy, the US, Canada, and Japan [15,16].
Historically, cCD was associated with high levels of neonatal morbidity and mortality,
although nowadays, it is clear that most cases are asymptomatic [13, 15]. Some cCD cases can
present nonspecific symptoms, if any, as seen in other intrauterine or perinatal infections (like
Toxoplasma gondii, Treponema pallidum, rubella virus, cytomegalovirus, HIV, herpes simplex
virus, and parvovirus infections). Therefore, detection of T. cruzi congenital infection should
rely on easy-to-use and point-of-care diagnostic tools [17].
Congenital T. cruzi infection is an acute infection in newborns that should be treated with
antiparasitic therapy. Left untreated, the infection can progress to chronic CD later in life, with
a drop in the cure rate.
Targeted populations for prevention and control of congenital
transmission of T. cruzi
In order to eliminate congenital transmission of T. cruzi, efforts should be focused on 5 popu-
lation groups living within or outside of LA (as defined previously), namely the following:
1. Girls and female adolescents (pre–conceptional phase).
2. Women of fertile age not yet pregnant (childbearing age), by detecting T. cruzi infection
and treating those who are infected (aiming to prevent congenital transmission and reduce
the pool of infected population) [4–7]. Control of vectors in endemic areas of LA and blood
transmission in endemic as well as nonendemic areas have to be pursued to reduce the risk
of infection and the reservoir of infected women.
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3. Pregnant women, by antenatal screening for infection performed before or even when
entering in maternity. Among those who are infected, there is no way to identify in advance
those who will transmit the infection to their offspring, and there are no means of prevent-
ing such congenital infection at that moment (antiparasitic treatment is not recommended
during pregnancy, see “Treatment of infected girls or adults”). Infected mothers should be
treated after delivery and lactation period (see “Treatment of infected girls or adults”) (aim-
ing to prevent recurrent congenital transmission in successive gestations and reduce the
pool of infected population).
4. Neonates/infants born to infected mothers by investigating congenital infection and treat-
ing and following up all detected positive cases (aiming to control congenital infection,
reduce the pool of infected population, and to prevent further congenital transmission in
girls) [8].
5. Relatives and other children born to infected mothers (siblings) by investigating their infec-
tion status and treating all positive cases (aiming to reduce the pool of infected population
from index cases).
Recommendations for laboratory diagnosis
Detection of chronic infection in women
As previously recommended by WHO [18], it can be performed using at least 2 of the conven-
tional serological tests (indirect hemagglutination assay; indirect immunofluorescence assay;
or ELISA, based on crude or recombinant antigens) in order to increase diagnosis accuracy.
These tests are generally available at low cost in primary healthcare facilities. In cases of dis-
crepancies among 2 tests, serology will be repeated in a new sample, and if results remain
inconclusive, a third test (e.g., western blot) should be done. The highly sensitive chemilumi-
nescent immunoassay (CMIA) [19] can be used for screening as a stand-alone test (although it
remains logistically and economically prohibitive for resource-limited settings), but positive
results should be confirmed by conventional serological tests. All these diagnostic tests are not
point-of-care tests (they must be performed in a laboratory), and results are not immediately
available.
Rapid diagnostic tests detecting antibodies using distinct antigen sets are easy to use (whole
blood based, need neither electricity nor cold chain, and results are available within an hour
[20]). Used combined to limit discordant results [21], these screening tests could be of help for
pregnant women entering maternity facilities for delivery without previous serological diagno-
sis or at primary healthcare facilities in rural or remote areas. However, by waiting for field val-
idation at large scale, they can be considered as “uptaking” tests in order to prevent losing the
patient and also need confirmation with standard tests.
Molecular tests (see “Detection of congenital infection in neonates”) have low sensitivity in
the chronic phase of infection and can only be used as complementary diagnosis methods to
serological screening.
Detection of congenital infection in neonates
It can be performed by detecting living parasites in the umbilical cord or, preferably, venous
blood of the newborn. Parasitological techniques concentrate parasites by centrifugation using
capillary tubes (microhematocrit test) or Eppendorf tubes (“microstrout” method). Parasites
are investigated by microscopic examination of the blood buffy coat [8]. Direct detection of
the parasite in blood is facilitated by the fact that T. cruzi has a characteristic movement pattern
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and a relatively large size that allow its visualization by routine microscopy. If the test is negative
at birth, it should be repeated at one month of age, when the peak of parasitemia is usually ob-
served [7, 22–24]. These parasitological tests offer undisputable and definitive diagnosis of in-
fection and are considered as gold standards. However, they require time, prompt processing of
the sample (within 24 hours), adequately trained laboratory personnel, and quality controls—
factors that can influence accuracy and reliability of the results [13, 23]. Other parasitological
tests, based on multiplication of parasites, as hemoculture, are not routinely used for diagnosis
of congenital cases. They are “in house” made, require huge equipment with biological protec-
tion, in addition to well-trained personal, and demand several weeks to get a result and need
several milliliters of blood only available when using cord blood [24, 25]. Therefore, more sensi-
tive and automated tests are needed for early detection of very low levels of T. cruzi, particularly
when transmission occurs in the last period of pregnancy, close to or even at birth.
Molecular methods are another approach for early detection of infection in the blood. They
are promising and increasingly used (particularly in Europe), though they present some limita-
tions. They are still economically prohibitive for routine screening in resource-limited settings
[26]. False positive results may occur, particularly if samples are collected from umbilical cord
blood at birth [15, 27]. They lack standardization, leading to various sensitivity levels accord-
ing to the centers, and quality control programs are still not implemented enough [28]. As a
consequence, molecular methods require stronger and wider clinical validations before being
considered as gold standards to diagnose congenital infection. Thereby, the following factors
should be taken into account: the best timing of blood sampling (1 to 3 month[s] after birth
rather than at birth, unless in presence of a clinically ill newborn), the number of samples to be
taken, the sample collection process (EDTA, guanidine EDTA, filter paper, blood clot), the
DNA extraction procedure, the DNA target (satellite DNA and/or kinetoplast DNA), the type
of method (standard PCR or real-time PCR, requiring slightly more complex equipment and
higher cost), the quality control, and the biological standards [28–34]. Therefore, currently,
molecular tests can be considered as uptaking tests in order to prevent losing the patient dur-
ing the follow-up, when parasitological techniques are not available/reliable for logistical/orga-
nizational constraints or lack of skilled personnel. The loop-mediated isothermal amplification
(LAMP) appears as a promising novel diagnostic test because it uses a single tube, it does not
require a thermocycler, and results are viewable by the naked eye within an hour. Nevertheless,
it requires further validation for the diagnosis of congenital infection [35–37].
Histological examination of placenta or molecular detection of T. cruzi DNA in the placen-
tal tissues have limited sensitivity, and placental involvement does not closely correlate to fetal
infection [38, 39].
Detection of congenital infection in infants by serological tests when
maternal antibodies have disappeared
Serological tests for infants should be used as for mothers (see “Detection of chronic infection
in women”). Detection of T. cruzi–specific antibodies in infants older than 10 months of age
(i.e., after elimination of passively transferred maternal antibodies) indicates a congenital
infection (when previous transmission by vectors and blood transfusion has been ruled out).
By contrast, a negative serological result in infants (born to infected mother) at 10 months of
age or thereafter indicates an absence of congenital infection. Such detection of T. cruzi–spe-
cific antibodies in infants is a gold standard for diagnosis of cCD [8]. It should be performed
in all infants born to infected mothers if previous tests (parasitological and/or molecular meth-
ods) were negative or if no screening tests were done before. However, testing infants only at
10 months old delays diagnosis and treatment and increases the risk of loss to follow-up.
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Other tests detecting antibodies in blood, such as trypomastigote excreted-secreted antigens
blots IgM or shed acute-phase antigens (SAPA) ELISA IgG (detecting SAPA within the first 3
months of infection [22, 40]), are not commercially available and need to be validated at a
larger scale.
Health systems should evaluate and implement the strategies that facilitate the earliest pos-
sible diagnosis of congenital infection, taking into account the frequent poor compliance of
the mothers to attend follow-up visits to the health centers.
Recommendations for treatment
Treatment of infected neonates and infants
Cases of congenital T. cruzi infection should be treated as soon as the diagnosis has been con-
firmed. The current experience of expert clinical groups in treating congenital T. cruzi infec-
tion confirms that (i) both benznidazole (BZ) and nifurtimox (NF) can be used to treat
congenital cases; (ii) the recommended dose of BZ in infants is 5 to 7 mg/kg per day, divided
in 2 doses, and that of NF is 10 to 15 mg/kg per day, divided in 3 doses; (iii) such doses can be
administered orally in one dose in low-weight neonates; precautions should be taken to obtain
appropriate dosage of active drug, particularly with no dispersal tablets (see point v), which
have to be crushed and used as a suspension; (iv) the recommended duration of treatment is
60 days and should not be<30 days [41]; (v) BZ is available in dispersal tablets of 12.5 mg and
NF in tablets of 120 mg (dispersal tablets of 30 mg should be available proximately). Both
drugs can be obtained free of charge near WHO (NF for patients of all ages and BZ for patients
aged under 19 years).
Current expert field experience indicates that treatment is highly effective with lower
adverse events than those described in adults [42]. Cure rates, as evaluated by conventional
serology, are over 90% in infants treated during the first year of age. Randomized comparative
clinical trials in infants or trials combining BZ or NF with new chemical entities are strongly
desired to adjust/optimize the dose and/or duration of treatment.
Treatment follow-up is recommended by parasitological and/or molecular tests in the
weeks after the treatment onset for neonates displaying parasitemia. After treatment comple-
tion, patients need to be followed every 6 months with quantitative serological tests. The
patient is considered cured when serology becomes negative.
Treatment of infected girls or adults
They should be treated with BZ or NF according to the standard recommendations of WHO
[18]. However, antiparasitic treatment is contraindicated during pregnancy, because the risks
of using the available medicines BZ and NF on the fetus are unknown, and the risk of adverse
reactions is high in adults [43]. Infected mothers will be therefore treated after delivery and the
lactation period to avoid interruption of lactation as a result of such possible adverse reactions.
Other recommendations
Clinical evaluation and follow-up are required for mothers displaying cardiac and/or digestive
forms of CD [18]. It is recommended that infected mothers do not donate blood and that cord
blood from neonates born to infected mothers is not used for bone marrow transplantation,
due to the risk of inducing an acute CD in an immunosuppressed recipient [44].
CD should be systematically investigated in relatives and other children born to infected
mothers (serological diagnosis), and positive cases should be clinically evaluated and treated
accordingly.
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Recommendations for healthcare systems and public health organizations
The barriers to healthcare access should be reduced to facilitate the diagnosis of CD and avoid
loss to follow-up in the target populations.
Awareness, education, and training of healthcare workers at different levels on prevention
and control strategy of cCD have to be improved, as well as the cooperation among the pri-
mary healthcare, hospital, and public health actors.
Information, education, and communication on cCD should be strengthened within com-
munity and patient associations with commitment of community health workers near the
affected population.
Detection of cCD has to be integrated within programs aiming to detect other congenital
infections (e.g., HIV, syphilis, hepatitis B, and the other intrauterine or perinatal infections
mentioned previously) [45].
Epidemiological information systems and notification and monitoring of cases and health
risks (as population profiles rapidly change due to their mobility in times of economic con-
straints [46]) have to be promoted and implemented in order to obtain more accurate infor-
mation on prevalence of infection in pregnant women and incidence of congenital cases and
verify the process of interruption of transmission. This can be done through the recently
updated WHO information system to control/eliminate NTDs (WISCENTD) and its WHO
integrated data platform (WIDP) [47].
Control strategy of cCD has been shown to be cost saving [48–51], fully justifying its inte-
gration at the public health level.
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T, et al. Economic evaluation of Chagas disease screening in Spain. Acta Trop. 2015; 148: 77–88.
https://doi.org/10.1016/j.actatropica.2015.04.014 PMID: 25917718
51. Stillwaggon E, Perez-Zetune V, Bialek SR, Montgomery SP. Congenital Chagas Disease in the United
States: Cost Savings through Maternal Screening. Am J Trop Med Hyg. 2018; 98: 1733–1742. https://
doi.org/10.4269/ajtmh.17-0818 PMID: 29714163
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007694 October 24, 2019 9 / 9
